RxDoctor Payments Data

Brittany Roberts, APRN

Family · Summerville, SCNPI 1497172779

Payments from drug & device makers

$4,271in general payments, 2019–2025

Across 233 payments — averaging $18.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$568
  • AbbVie$532
  • GSK$263
  • Novo Nordisk$206
  • Xeris Pharmaceuticals, Inc.$190
  • Otsuka America Pharmaceutical, Inc.$169
  • plus $2K from 53 others

What the payments were for

  • Food & beverage$4,271100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,271 in reported general payments places this provider in the 90th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$98,403
Medicare patients
346
Services billed
1,966

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide100$121,719
EliquisApixaban69$60,427
Breztri AerosphereBudesonide/Glycopyr/Formoterol43$50,946
JardianceEmpagliflozin48$50,070
MounjaroTirzepatide34$34,421
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$33,776
FarxigaDapagliflozin Propanediol20$23,398
XareltoRivaroxaban23$19,842
MyrbetriqMirabegron11$8,952
Omeprazole264$3,580
Albuterol Sulfate HfaAlbuterol Sulfate131$3,536
Atorvastatin Calcium424$3,485
Gabapentin145$2,677
Qvar RedihalerBeclomethasone Dipropionate12$2,588
Rosuvastatin Calcium186$2,337

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$206$121,719100 claims
AstraZenecaBreztri Aerosphere, Farxiga$568$74,34463 claims
PfizerEliquis$137$60,42769 claims
Boehringer IngelheimJardiance$142$50,07048 claims
Lilly USA, LLCMounjaro$94$34,42134 claims
GSKTrelegy Ellipta$263$33,77650 claims
Johnson & JohnsonXarelto$88$19,84223 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$14$1,902220 claims
AbbVieSynthroid$532$98622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,248 family providers in South Carolina.

Other family in Summerville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →